Iparomlimab and Tuvonralimab in HNSCC | MicrobiomeTrials← Back to trialsNCT07090317
Iparomlimab and Tuvonralimab in HNSCC
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-29Est. Completion: 2027-08-01
Enrollment target: 30 participants Locations- the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in
Borderline Resectable CarcinomaUnresectable CancerEsophageal Squamous Cell Carcinoma (ESCC)Immune Checkpoint InhibitorChemotherapyRadiotherapyTislelizumab
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and…
Shantou, ChinaEst. completion Nov 1, 2028
Recurrent Solid Tumor
Advanced Solid Tumor
Urinary Bladder Neoplasm
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Renal Pelvis Cancer
Bladder Cancer
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in particip…
Duarte, United StatesEst. completion May 2027